Men with PSA-Only Relapse Might Safely Defer Androgen Deprivation Therapy, Study Suggests — Physician’s First Watch
Men with PSA-Only Relapse Might Safely Defer Androgen Deprivation Therapy, Study Suggests
By Amy Orciari Herman
For men who develop prostate-specific–antigen relapse alone after treatment for prostate cancer, immediate initiation of androgen-deprivation therapy (ADT) offers no survival benefit over delayed ADT, according to an abstract from an observational study released on Wednesday.
Using a national cancer registry, researchers studied some 2000 men with PSA relapse and no other signs of cancer recurrence who either underwent immediate ADT or deferred treatment for at least 2 years or until they developed metastasis, symptoms, or worsened PSA. During some 4.5 years' follow-up, neither all-cause mortality nor prostate-cancer–specific mortality differed between the groups.
The study will be presented later this month at the annual meeting of the American Society of Clinical Oncology.